Page last updated: 2024-10-25

deferiprone and Dermatitis Medicamentosa

deferiprone has been researched along with Dermatitis Medicamentosa in 3 studies

Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.

Research Excerpts

ExcerptRelevanceReference
" We conclude that the short-term use of L1, with or without DFO, was safe and efficacious in our Chinese patient cohort."2.72A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong. ( Chan, GC; Chik, KW; Ha, SY; Lam, CW; Lee, AC; Ling, SC; Luk, CW; Ng, IO, 2006)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's2 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Totadri, S1
Bansal, D1
Bhatia, P1
Attri, SV1
Trehan, A1
Marwaha, RK1
Balocco, M1
Carrara, P1
Pinto, V1
Forni, GL1
Ha, SY1
Chik, KW1
Ling, SC1
Lee, AC1
Luk, CW1
Lam, CW1
Ng, IO1
Chan, GC1

Trials

1 trial available for deferiprone and Dermatitis Medicamentosa

ArticleYear
A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.
    Hemoglobin, 2006, Volume: 30, Issue:2

    Topics: Adolescent; Adult; Arthralgia; beta-Thalassemia; Biopsy, Needle; Chelation Therapy; Child; Combined

2006

Other Studies

2 other studies available for deferiprone and Dermatitis Medicamentosa

ArticleYear
The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
    Pediatric blood & cancer, 2015, Volume: 62, Issue:9

    Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Chemical and Drug Induced Liver I

2015
Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
    American journal of hematology, 2010, Volume: 85, Issue:6

    Topics: Administration, Oral; Arthralgia; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Defer

2010